[1] |
中华医学会肝病学分会. 肝硬化诊治指南[J]. 中华肝脏病杂志, 2019, 27(11): 846-865.
|
[2] |
Ginès P, Krag A, Abraldes JG, et al. Liver cirrhosis[J]. Lancet (London, England), 2021, 398(10308): 1359-1376.
|
[3] |
许波银, 李娴, 蔡花, 等. 综合医院ICU患者及环境分离多重耐药菌耐药率及同源性[J]. 中国感染控制杂志, 2023, 22(4): 404-410.
|
[4] |
余跃天, 马朋林. 重症监护病房多重耐药菌防控:指南与实践[J]. 中华医学杂志, 2019, 99(25): 1945-1948.
|
[5] |
Fernández J, Prado V, Trebicka J, et al. Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe[J]. J Hepatol, 2019, 70(3): 398-411.
doi: S0168-8278(18)32511-X
pmid: 30391380
|
[6] |
中华人民共和国卫生部. 医院感染诊断标准(试行)[J]. 中华医学杂志, 2001, 81(5): 314-320.
|
[7] |
王家良. 临床流行病学一临床科研设计、衡量与评价[M]. 上海: 上海科学技术出版社, 2001.
|
[8] |
徐小元, 丁惠国, 李文刚, 等. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11):2408-2425.
|
[9] |
Sanchez LO, Gustot T. Multidrug-resistant bacterial infection in patients with cirrhosis.A review[J]. Curr Hepatol Rep, 2019, 18(1): 28-35.
|
[10] |
GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: A systematic analysis for the global burden of disease study 2016[J]. Lancet (London, England), 2017, 390(10100): 1151-1210.
|
[11] |
Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance[J]. J Hepatol, 2014, 61(6):1385-1396.
doi: 10.1016/j.jhep.2014.08.010
pmid: 25135860
|
[12] |
European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69(2): 406-460.
doi: S0168-8278(18)31966-4
pmid: 29653741
|
[13] |
Bastida C, Hernández-Tejero M, Aziz F, et al. Meropenem population pharmacokinetics in patients with decompensated cirrhosis and severe infections[J]. J Antimicrob Chemother, 2020, 75(12): 3619-3624.
doi: 10.1093/jac/dkaa362
pmid: 32887993
|
[14] |
Fernández J, Piano S, Bartoletti M, et al. Management of bacterial and fungal infections in cirrhosis: The MDRO challenge[J]. J Hepatol, 2021, 75:S101-S117.
|
[15] |
吴美飞, 刘秀凤, 张磊. HIF-2α在肝脏疾病中的作用及机制研究进展[J]. 安徽医科大学学报, 2024, 59(6): 1098-1102.
|
[16] |
Hotchkiss RS, Moldawer LL, Opal SM, et al. Sepsis and septic shock[J]. Nature Reviews Disease Primers, 2016, 2(1):16045.
|
[17] |
Onorato L, Monari C, Capuano S, et al. Prevalence and therapeutic management of infections by Multi-Drug-Resistant Organisms (MDROs) in patients with liver cirrhosis: A narrative review[J]. Antibiotics (Basel, Switzerland), 2022, 11(2): 232.
|